PolyPid Ltd. Ordinary Shares (PYPD) Stock Price

PYPDStock
$4.72+40.90%52W
Market Cap$95.87M
P/E—
PEG Ratio—
Div yield—
Beta1.48

PYPD Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-3.12%
Price vs S&P 500 (4W)-7.38%
VGM Score60.97

PYPD Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.38-$0.35+7.28%(+$0.03)
Q1 2026-$0.43-$0.35+19.23%(+$0.08)
Q4 2025-$0.33-$0.41-24.24%(-$0.08)
Q3 2025-$0.52-$0.37+29.19%(+$0.15)
Q2 2025-$0.55-$0.78-42.47%(-$0.23)

PYPD Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.10
4.10
4.10
4.10

Industry Peers — Surgical & Medical Instruments(142)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth (5Y)Gross Margin (TTM)Operating Margin (TTM)Price
PYPDPolyPid Ltd. Ordinary Shares
——B————$4.72
SYKStryker CorporationCBC4.4x11.8%65.3%21.3%$294.66
MMM3M CompanyCDB3.4x-5.0%39.4%18.4%$164.75
BSXBoston Scientific Corp.CBC3.1x15.2%69.5%19.8%$44.39
BDXBecton, Dickinson and Co.BDA2.5x6.3%46.7%9.6%$191.75
MDLNMedline Inc. Class A common stockCDC1.6x—26.2%6.0%$35.96
RMDResMed Inc.CCB5.9x12.1%61.1%33.4%$238.97
DXCMDexCom, Inc.CBB6.5x19.3%64.3%22.9%$86.04
WSTWest Pharmaceutical Services, Inc.DCA8.5x7.4%36.8%20.4%$384.02
SOLVSolventum CorporationCCB1.8x—54.8%23.9%$85.81
BAXBaxter International Inc.BDB1.1x-0.8%30.7%-2.3%$25.28

About PolyPid Ltd. Ordinary Shares

PolyPid Ltd is a clinical-stage biopharmaceutical company developing therapies based on PLEX, its proprietary drug delivery technology that enables targeted, localized drug release over extended periods. The company's lead candidate, D-PLEX100, is being developed to prevent surgical site infections, while OncoPLEX represents a potential intra-tumoral cancer treatment platform.